Last reviewed · How we verify

Denosumab (CP2)

Amgen · Phase 3 active Small molecule

Denosumab (CP2) is a RANKL inhibitor (monoclonal antibody) Small molecule drug developed by Amgen. It is currently in Phase 3 development for Prevention of skeletal-related events in patients with bone metastases from solid tumors, Treatment of giant cell tumor of bone, Osteoporosis in postmenopausal women and men at high risk of fracture. Also known as: XGEVA®.

Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.

Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption. Used for Prevention of skeletal-related events in patients with bone metastases from solid tumors, Treatment of giant cell tumor of bone, Osteoporosis in postmenopausal women and men at high risk of fracture.

At a glance

Generic nameDenosumab (CP2)
Also known asXGEVA®
SponsorAmgen
Drug classRANKL inhibitor (monoclonal antibody)
TargetRANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
ModalitySmall molecule
Therapeutic areaOncology, Bone Metabolism
PhasePhase 3

Mechanism of action

Denosumab binds to RANKL, a key mediator of osteoclast differentiation and activation. By preventing RANKL from engaging its receptor RANK on osteoclast precursors, the drug suppresses bone resorption and increases bone mineral density. This mechanism makes it effective for conditions characterized by excessive bone loss or osteoclast-mediated bone destruction.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Denosumab (CP2)

What is Denosumab (CP2)?

Denosumab (CP2) is a RANKL inhibitor (monoclonal antibody) drug developed by Amgen, indicated for Prevention of skeletal-related events in patients with bone metastases from solid tumors, Treatment of giant cell tumor of bone, Osteoporosis in postmenopausal women and men at high risk of fracture.

How does Denosumab (CP2) work?

Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.

What is Denosumab (CP2) used for?

Denosumab (CP2) is indicated for Prevention of skeletal-related events in patients with bone metastases from solid tumors, Treatment of giant cell tumor of bone, Osteoporosis in postmenopausal women and men at high risk of fracture.

Who makes Denosumab (CP2)?

Denosumab (CP2) is developed by Amgen (see full Amgen pipeline at /company/amgen).

Is Denosumab (CP2) also known as anything else?

Denosumab (CP2) is also known as XGEVA®.

What drug class is Denosumab (CP2) in?

Denosumab (CP2) belongs to the RANKL inhibitor (monoclonal antibody) class. See all RANKL inhibitor (monoclonal antibody) drugs at /class/rankl-inhibitor-monoclonal-antibody.

What development phase is Denosumab (CP2) in?

Denosumab (CP2) is in Phase 3.

What are the side effects of Denosumab (CP2)?

Common side effects of Denosumab (CP2) include Hypocalcemia, Osteonecrosis of the jaw, Atypical femoral fractures, Infections, Fatigue.

What does Denosumab (CP2) target?

Denosumab (CP2) targets RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand) and is a RANKL inhibitor (monoclonal antibody).

Related